ERBB2 and cancer: Notable examples are inhibitors targeting tyrosine kinases, such as ALK (crizotinib), Bcr-Abl (imatinib) and HER2 (trastuzumab), which are aberrantly active due to genetic alterations.46, 47, 48, 49 Nevertheless, there is a poor correlation between effectiveness of emerging anti-cancer agents in cell culture and ultimate treatment success rates in patients, which are low and need improvement.50 Culture conditions impact the regulation of cell fate and responsiveness to external stimuli.